| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | 0.045 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.8 |